Intestinal Pseudo Obstruction Treatment Global Market Report 2024

The intestinal pseudo obstruction treatment market size has grown strongly in recent years. It will grow from $23.63 billion in 2023 to $24.98 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historical period can be attributed to several factors, including an increase in chronic respiratory diseases, heightened patient preference and compliance, the convenience of self-administration, expanded applications in pediatrics, market growth in allergic rhinitis treatment, and a broader range of indications.

The intestinal pseudo obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $30.87 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing geriatric population, a rise in global respiratory issues, expanding applications in neurological disorders, trends in personalized medicine, initiatives in preventive healthcare, and market penetration in emerging economies. Key trends expected in the forecast period include advancements in formulation technologies, a heightened focus on pediatric and geriatric applications, an increase in self-administration devices, the emergence of nasal powder inhalers, and the incorporation of biologics and peptides.

The anticipated rise in the prevalence of gastrointestinal diseases is poised to propel the expansion of the market for intestinal pseudo-obstruction treatment in the coming years. Gastrointestinal diseases, also known as digestive disorders, encompass a broad spectrum of conditions affecting the GI tract, the passage extending from the mouth to the anus. These diseases give rise to various complications, including intestinal pseudo-obstruction, emphasizing the need for the development and provision of effective treatments to address associated symptoms. As an illustration, in January 2023, the American Cancer Society (ACS) reported a 3.18% increase in gastrointestinal cancers in the United States, reaching 348,840 cases compared to 338,090 in 2021. This escalation in the prevalence of gastrointestinal diseases is expected to be a driving force behind the growth of the intestinal pseudo-obstruction treatment market.

The escalating incidence of Parkinson’s disease (PD) is projected to be a catalyst for the expansion of the intestinal pseudo-obstruction treatment market in the foreseeable future. Parkinson's disease, characterized by chronic neurodegeneration affecting the central nervous system and manifesting in symptoms such as tremors, rigidity, bradykinesia, and postural instability, is associated with non-motor symptoms such as constipation and intestinal pseudo-obstruction. This scenario necessitates the development and provision of effective treatments to address these symptoms. For example, a 2022 research initiative supported by the Parkinson's Foundation revealed that nearly 90,000 individuals in the United States are diagnosed with Parkinson's disease annually, marking a 50% increase from the previously anticipated rate of 60,000 diagnoses per year. Furthermore, it is expected that the population of individuals with Parkinson’s disease (PD) will reach 1.2 million by 2030. Hence, the rising incidence of Parkinson's disease (PD) is poised to be a key driver for the growth of the intestinal pseudo-obstruction market.

The anticipated high cost of treatment is poised to act as a hindrance to the growth of the intestinal pseudo-obstruction treatment market. The expected elevated expenses associated with treatment are likely to create barriers to accessibility, potentially limiting patient adoption due to financial constraints and economic considerations. As an illustration, data from Wellness Destination India.com in January 2023, an India-based medical tourism company, revealed that the cost for intestinal obstruction surgery in India for international patients ranged between USD 6,000 to USD 6,500, indicating a significant financial burden. Consequently, the substantial cost of treatment has the potential to impede the growth of the intestinal pseudo-obstruction treatment market.

Prominent companies within the intestinal pseudo-obstruction treatment market are actively engaged in the development of innovative drug therapies, such as NHE3 inhibitor treatment therapy, to offer reliable services to customers. NHE3 inhibitor treatment therapy involves medication that functions by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, introduced IBSRELA, an NHE3 inhibitor treatment designed for irritable bowel syndrome with constipation (IBS-C) in adults. This therapy holds the potential to enhance gastrointestinal motility. IBSRELA operates by inhibiting or blocking the activity of the Sodium-Hydrogen Exchanger 3 (NHE3) protein, leading to improved sodium and water absorption in the intestines and intestinal tract. This mechanism ultimately enhances gastrointestinal motility and alleviates symptoms associated with intestinal pseudo-obstruction.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic acquisition is poised to enhance Ironwood's innovation pipeline and overall portfolio, aiming to redefine the standard of care for patients with gastrointestinal (GI) conditions and advance the treatment of GI illnesses. VectivBio Holding AG, based in Switzerland, is a clinical-stage biotechnology company specializing in the treatment of severe and rare gastrointestinal conditions, including intestinal pseudo-obstruction (IPO).

Major companies operating in the intestinal pseudo obstruction treatment market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Olympus Corporation, Steris PLC, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Inc., Carestream Health, Ironwood Pharmaceuticals Inc., Fujifilm Healthcare Solutions, Basilea Pharmaceutica Ltd., Melinta Therapeutics LLC, VectivBio AG, Tetraphase Pharmaceuticals, Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo obstruction treatment market in 2023. The regions covered in the intestinal pseudo obstruction treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intestinal pseudo-obstruction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intestinal pseudo-obstruction treatment involves medical interventions and therapies aimed at managing a rare condition characterized by the obstruction of the intestine (bowels) without any physical blockage. Symptoms of intestinal pseudo-obstruction include abdominal pain, bloating, nausea, and vomiting. The approach to treating chronic intestinal pseudo-obstruction includes adjustments to diet, nutrition assistance, medications, decompression, and other therapeutic measures.

The primary categories of conditions in intestinal pseudo-obstruction treatment are acute and chronic. Acute refers to the sudden onset or rapid development of symptoms or a medical condition. Various treatments, such as medication, surgery, diet adjustments, and others, are employed with diagnoses conducted through physical examination, biopsy, blood tests, gastric emptying tests, imaging tests, and other diagnostic methods. End users of these treatments include hospitals and clinics, ambulatory care centers, and other healthcare facilities.

The intestinal pseudo obstruction treatment market research report is one of a series of new reports that provides intestinal pseudo obstruction treatment market statistics, including intestinal pseudo obstruction treatment industry global market size, regional shares, competitors with a intestinal pseudo obstruction treatment market share, detailed intestinal pseudo obstruction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the intestinal pseudo obstruction treatment industry. This intestinal pseudo obstruction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestinal pseudo-obstruction treatment market consists of revenues earned by entities by providing diagnostic services such as metabolic panel tests, manometry, and serum electrolyte level tests that help in diagnosing and monitoring patients with intestinal pseudo-obstruction. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction market also includes sales of drug types such as antibiotics, antidepressants, and antidiarrheals that are used in treating intestinal pseudo-obstruction. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.